The treated groups exhibited an average improvement in this ratio of +55.1% (supplement), +39.4% (lotion) and +63.5% (combination), whereas the control group experienced a slight decrease of 3.9%
Our technical specialists can help you design the right workflow, select suitable sample types, and interpret your results in the context of your broader research goals
Clinical monitoring is recommended for selected medications with absorption-sensitive profiles, particularly levothyroxine
Weight-Related Outcomes and Adiposity Metrics In the Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity (SELECT) trial [61], semaglutide reduced major adverse cardiovascular events by 20% in adults with cardiovascular disease, overweight or obesity, and no diabetes
Access the study via PubMed, PMID: 38999752